Forbion European Acquisition and enGene sign merger deal

Forbion European Acquisition has entered a definitive business combination agreement with biotechnology company enGene to create a combined biotechnology company to develop next-generation non-viral, locally administered gene therapies.

The combined company will be named enGene Holdings and its common shares are expected to be listed on the Nasdaq.

Funding for the deal includes $20m from the existing investment of Forbion Growth in FEAC Class A shares, along with PIPE investment, other private investment and a non-redemption commitment of almost $115m.

This financing is supported by Forbion Growth with participation from new institutional and existing investors Lumira Ventures, Fonds de solidarité FTQ and Forbion Ventures III.

Other investors include Investissement Québec, Omega Funds, Cowen Healthcare Investments, CTI Life Sciences Fund III, Northleaf Capital Partners, BVF Partners and Vivo Capital.

The proposed transaction will conclude in the second half of 2023.

enGene CEO Jason Hanson said: “Our mission at enGene is to broaden the reach of gene therapy by creating safe, locally deliverable, non-viral therapies while freeing physicians from the onerous handling procedures typically required by viral-based gene therapy products.

“The proposed business combination with FEAC will enable us to build on the favourable safety and promising preliminary efficacy data from the Phase I portion of our Phase I/II LEGEND clinical trial of intravesical detalimogene voraplasmid, which we believe has the potential to set a new bar for organ-sparing NMIBC [non-muscle invasive bladder cancer] treatments and serve as the cornerstone of a multi-indication franchise.”

Net proceeds from the transaction are expected to be used to finance the clinical development of enGene’s lead product, intravesical detalimogene voraplasmid (EG-70).

The therapy is currently being developed to treat Bacillus Calmette-Guérin (BCG)-resistant NMIBC with carcinoma-in-situ.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

By Cytiva Thematic

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy